Compare TPVG & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPVG | BNTC |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.9M | 396.3M |
| IPO Year | 2013 | 2020 |
| Metric | TPVG | BNTC |
|---|---|---|
| Price | $4.89 | $9.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $5.83 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 243.3K | 125.6K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | ★ 18.93% | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.96 | N/A |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.40 | $9.26 |
| 52 Week High | $6.95 | $16.76 |
| Indicator | TPVG | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 33.18 |
| Support Level | $4.48 | N/A |
| Resistance Level | $4.90 | $13.49 |
| Average True Range (ATR) | 0.13 | 0.72 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 26.78 | 16.93 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.